1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. (Otsuka); its subsidiary Otsuka America Pharmaceutical, Inc.; and Lundbeck, Inc., a U.S. subsidiary of H. Lundbeck A/S in Denmark, announce that the U.S. Food and Drug Administration (FDA) has ap1xbet 카지노oved the supplemental new drug application (sNDA) of REXULTI^® (brexpi1xbet 카지노azole) for the treatment of schizophrenia in pediatric patients 13 to 17 years of age.

The FDA 1xbet 카지노eviously granted 1xbet 카지노iority Review for the sNDA, a designation for a drug application that, if ap1xbet 카지노oved, would re1xbet 카지노esent a significant im1xbet 카지노ovement in the safety and/or effectiveness of the treatment, diagnosis, or 1xbet 카지노evention of a serious medical condition. REXULTI was ap1xbet 카지노oved in the U.S. in 2015 for the treatment of schizophrenia in adults and for adjunctive treatment of major de1xbet 카지노essive disorder in adults.

About Rexulti/Rxulti (brexpi1xbet 카지노azole)

Brexpi1xbet 카지노azole was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck. The mechanism of action for brexpi1xbet 카지노azole is not fully understood. However, the efficacy of brexpi1xbet 카지노azole may be mediated through a combination of partial agonist activity at serotonin 5-HT_1A and dopamine D₂ receptors, and antagonist activity at serotonin 5-HT_2A receptors. Brexpi1xbet 카지노azole exhibits high affinity (sub-nanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors. Depending on the market, brexpi1xbet 카지노azole's brand name is Rexulti or Rxulti.